Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.48 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.41 |
| ▸ | KIF11 | P52732 | 9/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL453502 | 0.89 | KCNN4 (0.46) | TAAR1KCNN4KIF11CYP2C19HIF1A | |
| SCHEMBL7004942 | 0.83 | TAAR1 (0.52) | TAAR1KCNN4KIF11CYP3A4CYP2D6 | |
| SCHEMBL28118448 | 0.82 | KCNN4 (0.39) | TAAR1KCNN4KIF11CYP2C19HIF1A | |
| SCHEMBL1139107 | 0.79 | CYP2C19 (0.53) | KIF11CYP2C19HIF1ACYP3A4CYP2D6 | |
| SCHEMBL7125763 | 0.79 | CYP1A2 (0.38) | TAAR1KCNN4KIF11KCNH2CYP2D6 | |
| SCHEMBL1139315 | 0.79 | CYP2C19 (0.53) | KIF11CYP2C19HIF1ACYP3A4CYP2D6 | |
| SCHEMBL9425766 | 0.78 | TAAR1 (0.52) | TAAR1KCNN4KIF11 | |
| SCHEMBL157809 | 0.78 | KCNN4 (0.48) | TAAR1KCNN4KIF11CYP2D6 | |
| Hydrochloric Acid SCHEMBL9426177 | 0.77 | TAAR1 (0.50) | TAAR1KCNN4KIF11CYP2C19CYP3A4 | |
| SCHEMBL1261574 | 0.77 | KIF11 (0.44) | TAAR1KCNN4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119905295-A | Anti-folding flame-retardant data cable and preparation method thereof | 杭州兴发科技股份有限公司 | 2025-04-29 | — | — | CN | claimed |
| CN-117727496-B | Silicon rubber insulation special power cable | 源鑫线缆有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-117727496-A | Silicon rubber insulation special power cable | 源鑫线缆有限公司 | 2024-03-19 | — | — | CN | claimed |
| EP-3154937-A1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | Fina Technology, Inc. (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191721-A1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | FINA TECHNOLOGY, INC. (US) | 2015-12-17 | — | — | WO | claimed |
| CN-119905295-A | Anti-folding flame-retardant data cable and preparation method thereof | 杭州兴发科技股份有限公司 | 2025-04-29 | — | — | CN | disclosed |
| CN-117727496-B | Silicon rubber insulation special power cable | 源鑫线缆有限公司 | 2024-07-02 | — | — | CN | disclosed |
| EP-3154937-B1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | FINA TECHNOLOGY (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117727496-A | Silicon rubber insulation special power cable | 源鑫线缆有限公司 | 2024-03-19 | — | — | CN | disclosed |
| EP-3096751-B1 | 12-EPI-PLEUROMUTILINS | Nabriva Therapeutics GmbH (AT) | 2021-01-06 | — | — | EP | disclosed |
| CN-105916499-B | 12-epi-pleuromutilins | 纳布里瓦治疗股份公司 | 2020-02-18 | — | — | CN | disclosed |
| US-9701628-B2 | 12-epi pleuromutilins | NABRIVA THERAPEUTICS AG (AT) | 2017-07-11 | — | — | US | disclosed |
| US-8202910-B2 | Compositions and methods for treatment of infectious disease | SEQUELLA, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2011-05-19 | — | — | US | disclosed |
| US-7842729-B2 | Anti tubercular drug: compositions and methods | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2010-11-30 | — | — | US | disclosed |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | SEQUELLA, INC. | 2009-07-30 | — | — | US | disclosed |
| US-7456222-B2 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-07-06 | — | — | US | disclosed |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | SEQUELLA, INC. | 2006-01-26 | — | — | US | disclosed |
| US-6951961-B2 | Methods of use and compositions for the diagnosis and treatment of infectious disease | GOVERNMENT OF THE UNITED STATES OF AMERICA REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2005-10-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118307-A1 | Compositions and methods for the treatment of infectious diseases | TERT, C5, ELANE | TAAR1 1357/4885KCNN4 4779/4885KIF11 3841/4885 |
| US-20090192173-A1 | ANTI-TUBERCULAR DRUGS: COMPOSITIONS AND METHODS | RIF1, TERT, ELL | TAAR1 2139/4885KCNN4 4472/4885KIF11 3858/4885 |
| US-20060148904-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | TAAR1 937/4885KCNN4 4817/4885KIF11 4014/4885 |
| US-20060020041-A1 | Anti tubercular drug: compositions and methods | C5, DERA, ELL | TAAR1 937/4885KCNN4 4817/4885KIF11 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.